Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 14, 2017; 23(34): 6287-6293
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6287
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6287
Stage group | BMI category | n | Median overall survival, mo (95%CI) | HR | 95%CI | P value | Ptrend value |
Overall | < 18.5 | 98 | 8.0 (5.8-11.3) | 1.12 | 0.83-1.52 | 0.45 | |
18.5-22.9 | 588 | 9.7 (8.7-11.1) | 1.00 | Ref. | Ref. | ||
23-27.4 | 791 | 9.5 (8.6-10.5) | 0.99 | 0.87-1.14 | 0.92 | ||
≥ 27.5 | 306 | 9.8 (7.6-11.2) | 1.05 | 0.88-1.25 | 0.61 | 0.90 | |
Resectable | < 18.5 | 15 | 11.1 (3.3-19.3) | 1.92 | 0.74-5.01 | 0.18 | |
18.5-22.9 | 73 | 15.6 (10.1-21.3) | 1.00 | Ref. | Ref. | ||
23-27.4 | 93 | 16.7 (11.9-27.4) | 0.92 | 0.59-1.44 | 0.71 | ||
≥ 27.5 | 36 | 16.2 (4.5-23.7) | 1.13 | 0.61-2.08 | 0.70 | 0.99 | |
Unresectable locally advanced | < 18.5 | 17 | 7.0 (3.4-26.1) | 0.83 | 0.38-1.84 | 0.65 | |
18.5-22.9 | 108 | 8.7 (7.3-11.7) | 1.00 | Ref. | Ref. | ||
23-27.4 | 143 | 8.6 (6.8-11.5) | 1.03 | 0.73-1.45 | 0.86 | ||
≥ 27.5 | 48 | 8.6 (4.9-15.6) | 0.95 | 0.59-1.54 | 0.84 | 0.90 | |
Metastatic | < 18.5 | 66 | 4.9 (2.8-8.0) | 1.07 | 0.76-1.51 | 0.70 | |
18.5-22.9 | 407 | 5.5 (4.0-6.4) | 1.00 | Ref. | Ref. | ||
23-27.4 | 555 | 5.7 (3.7-6.8) | 0.99 | 0.84-1.16 | 0.89 | ||
≥ 27.5 | 222 | 5.6 (3.3-7.7) | 1.02 | 0.84-1.27 | 0.76 | 0.88 |
- Citation: Jiang QL, Wang CF, Tian YT, Huang H, Zhang SS, Zhao DB, Ma J, Yuan W, Sun YM, Che X, Zhang JW, Chu YM, Zhang YW, Chen YT. Body mass index does not affect the survival of pancreatic cancer patients. World J Gastroenterol 2017; 23(34): 6287-6293
- URL: https://www.wjgnet.com/1007-9327/full/v23/i34/6287.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i34.6287